The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. In relation to Elosulfase alfa (Vimizim), the HSE has informed my Department that reimbursement arrangements have been in place since 29 March for both patients attending Temple Street Hospital.
I am also advised that the HSE's Primary Care Reimbursement Service (PCRS) has been invoiced by the hospital for the medicines and supply will continue for as long as clinically appropriate. However, long term treatment plans are a matter for an individual patient and their treating clinician.